



COPY OF PAPERS  
ORIGINALLY FILED

1614

Attorney Docket No.: 63.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Anker Steen Jorgensen

Serial No.: 09/995,987

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

Confirmation No: 3030

For: Glucagon Antagonists/Inverse Agonists

RECEIVED  
APR 25 2002  
TECH CENTER 1600/2900

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (1 Reference Total)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231


on April 15, 2002.

Sylvia Gonzalez

(name of person mailing paper)

(signature of person mailing paper)

**BEST AVAILABLE COPY**



Attorney Docket No. 6263.200-US

COPY OF PAPERS  
ORIGINALLY FILED

PATENT

#7  
LB  
5/13/02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Jorgensen et al

Application No.: 09/995,987

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

Confirmation No.: 3030

For: Glucagon Antagonists/Inverse Agonists

**RECEIVED**

APR 25 2002

TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed.

The reference is as follows:

1. WO 00/69810

**BEST AVAILABLE COPY**

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached reference.

The Information Disclosure Statement submitted herewith is being filed before the mailing date of a first Office Action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: April 15, 2002

Richard W. Bork  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

APR 23 2007

Sheet 1 of 1

**FORM PTO-1449**  
**(Rev. 2-32)**

U. S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

(Use several sheets if necessary)

Atty. Docket No. 6263.200-US

Serial No. 09/995,987

Applicant **Anker Steen Jorgensen**

Filing Date November 16, 2001

**Group To be assigned**

## U.S. PATENT DOCUMENTS

~~COPY OF PAPERS  
ORIGINALLY FILED~~

RECEIVED

APR 25 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**BEST AVAILABLE COPY**